<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26135599</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.</ArticleTitle><Pagination><StartPage>e0003903</StartPage><MedlinePgn>e0003903</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0003903</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0003903</ELocationID><Abstract><AbstractText>Dengue virus (DENV), a global disease, is divided into four serotypes (DENV1-4). Cross-reactive and non-neutralizing antibodies against envelope (E) protein of DENV bind to the Fc&#x3b3; receptors (Fc&#x3b3;R) of cells, and thereby exacerbate viral infection by heterologous serotypes via antibody-dependent enhancement (ADE). Identification and modification of enhancing epitopes may mitigate enhancement of DENV infection. In this study, we characterized the cross-reactive DB21-6 and DB39-2 monoclonal antibodies (mAbs) against domain I-II of DENV; these antibodies poorly neutralized and potently enhanced DENV infection both in vitro and in vivo. In addition, two enhancing mAbs, DB21-6 and DB39-2, were observed to compete with sera antibodies from patients infected with dengue. The epitopes of these enhancing mAbs were identified using phage display, structural prediction, and mapping of virus-like particle (VLP) mutants. N8, R9, V12, and E13 are the reactive residues of DB21-6, while N8, R9, and E13 are the reactive residues of DB39-2. N8 substitution tends to maintain VLP secretion, and decreases the binding activity of DB21-6 and DB39-2. The immunized sera from N8 substitution (N8R) DNA vaccine exerted greater neutralizing and protective activity than wild-type (WT)-immunized sera, both in vitro and in vivo. Furthermore, treatment with N8R-immunized sera reduced the enhancement of mortality in AG129 mice. These results support identification and substitution of enhancing epitope as a novel strategy for developing safe dengue vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Chung-Tao</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Pi-Chun</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>I-Ju</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Mei-Ying</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chiung-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Day-Yu</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Han-Chung</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan; Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26135599</ArticleId><ArticleId IdType="pmc">PMC4489899</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0003903</ArticleId><ArticleId IdType="pii">PNTD-D-15-00256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The global distribution and burden of dengue. Nature 496: 504&#x2013;507. 10.1038/nature12060</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster DP, Farrar J, Rowland-Jones S (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9: 678&#x2013;687. 10.1016/S1473-3099(09)70254-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(09)70254-3</ArticleId><ArticleId IdType="pubmed">19850226</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239: 476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Alvarez M, Halstead SB (2013) Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158: 1445&#x2013;1459. 10.1007/s00705-013-1645-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-013-1645-3</ArticleId><ArticleId IdType="pubmed">23471635</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422&#x2013;9427. 10.1073/pnas.0703498104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0703498104</ArticleId><ArticleId IdType="pmc">PMC1868655</ArticleId><ArticleId IdType="pubmed">17517625</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Coller BA, Clements DE (2011) Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391&#x2013;398. 10.1016/j.coi.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2011.03.005</ArticleId><ArticleId IdType="pubmed">21514129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM (1990) Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649&#x2013;688. 10.1146/annurev.mi.44.100190.003245</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003245</ArticleId><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz FX, Stiasny K (2012) Flaviviruses and their antigenic structure. J Clin Virol 55: 289&#x2013;295. 10.1016/j.jcv.2012.08.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2012.08.024</ArticleId><ArticleId IdType="pubmed">22999801</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7&#x2013;16. 10.1038/nrmicro2460</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2460</ArticleId><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3: 13&#x2013;22. 10.1038/nrmicro1067</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1067</ArticleId><ArticleId IdType="pubmed">15608696</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, et al. (2008) Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319: 1834&#x2013;1837. 10.1126/science.1153264</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153264</ArticleId><ArticleId IdType="pubmed">18369148</ArticleId></ArticleIdList></Reference><Reference><Citation>
Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, et al. (2003) Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology
306: 170&#x2013;180. doi: S0042682202000284
</Citation><ArticleIdList><ArticleId IdType="pubmed">12620809</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Delorey MJ, Chang GJ (2009) Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4: e4991 10.1371/journal.pone.0004991</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004991</ArticleId><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Chang GJ (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975&#x2013;13986. 10.1128/JVI.78.24.13975-13986.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.24.13975-13986.2004</ArticleId><ArticleId IdType="pmc">PMC533943</ArticleId><ArticleId IdType="pubmed">15564505</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">14696329</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell
108: 717&#x2013;725. doi: S0092867402006608
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152842</ArticleId><ArticleId IdType="pubmed">11893341</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986&#x2013;6991. 10.1073/pnas.0832193100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0832193100</ArticleId><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX (2001) Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75: 4268&#x2013;4275. 10.1128/JVI.75.9.4268-4275.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.9.4268-4275.2001</ArticleId><ArticleId IdType="pmc">PMC114172</ArticleId><ArticleId IdType="pubmed">11287576</ArticleId></ArticleIdList></Reference><Reference><Citation>Li PC, Liao MY, Cheng PC, Liang JJ, Liu IJ, et al. (2012) Development of a Humanized Antibody with High Therapeutic Potential against Dengue Virus Type 2. PLoS Negl Trop Dis 6: e1636 10.1371/journal.pntd.0001636</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001636</ArticleId><ArticleId IdType="pmc">PMC3341331</ArticleId><ArticleId IdType="pubmed">22563515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, et al. (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81: 12816&#x2013;12826. 10.1128/JVI.00432-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00432-07</ArticleId><ArticleId IdType="pmc">PMC2169112</ArticleId><ArticleId IdType="pubmed">17881453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Barrett AD (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349&#x2013;360. 10.1016/j.virol.2007.05.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2007.05.042</ArticleId><ArticleId IdType="pubmed">17719070</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, et al. (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109: 7439&#x2013;7444. 10.1073/pnas.1200566109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12&#x2013;20. 10.1016/j.virol.2012.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.03.003</ArticleId><ArticleId IdType="pmc">PMC3683589</ArticleId><ArticleId IdType="pubmed">22537810</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745&#x2013;748. 10.1126/science.1185181</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271&#x2013;283. 10.1016/j.chom.2010.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur MA, Sztein MB, Edelman R (2013) Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines 12: 933&#x2013;953. 10.1586/14760584.2013.815412</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2013.815412</ArticleId><ArticleId IdType="pmc">PMC3773977</ArticleId><ArticleId IdType="pubmed">23984962</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HC, Jung MY, Chiu CY, Chao TT, Lai SC, et al. (2003) Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J Gen Virol 84: 2771&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pubmed">13679612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Prestwood TR, Shresta S (2010) Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128&#x2013;139. 10.1016/j.chom.2010.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.01.004</ArticleId><ArticleId IdType="pmc">PMC2824513</ArticleId><ArticleId IdType="pubmed">20153282</ArticleId></ArticleIdList></Reference><Reference><Citation>Houng HH, Hritz D, Kanesa-thasan N (2000) Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3'-noncoding sequence. J Virol Methods 86: 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10713370</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2009) Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition (World Health Organization, Geneva). NBK143157. 23762963</Citation></Reference><Reference><Citation>Renukaradhya GJ, Suresh KB, Rajasekhar M, Shaila MS (2003) Competitive enzyme-linked immunosorbent assay based on monoclonal antibody and recombinant hemagglutinin for serosurveillance of rinderpest virus. J Clin Microbiol 41: 943&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150257</ArticleId><ArticleId IdType="pubmed">12624013</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM (2010) Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 10: 712&#x2013;722. 10.1016/S1473-3009(10)70166-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3009(10)70166-3</ArticleId><ArticleId IdType="pmc">PMC3057165</ArticleId><ArticleId IdType="pubmed">20883967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Silva AM (2011) The human antibody response to dengue virus infection. Viruses 3: 2374&#x2013;2395. 10.3390/v3122374</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3122374</ArticleId><ArticleId IdType="pmc">PMC3280510</ArticleId><ArticleId IdType="pubmed">22355444</ArticleId></ArticleIdList></Reference><Reference><Citation>
Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, et al. (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol
176: 2825&#x2013;2832. doi: 176/5/2825
</Citation><ArticleIdList><ArticleId IdType="pubmed">16493039</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SD, et al. (1988) Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A 85: 5259&#x2013;5263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281729</ArticleId><ArticleId IdType="pubmed">3134658</ArticleId></ArticleIdList></Reference><Reference><Citation>Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, et al. (2010) Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84: 10630&#x2013;10643. 10.1128/JVI.01190-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01190-10</ArticleId><ArticleId IdType="pmc">PMC2950583</ArticleId><ArticleId IdType="pubmed">20702644</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823 10.1371/journal.ppat.1000823</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000823</ArticleId><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84: 9227&#x2013;9239. 10.1128/JVI.01087-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01087-10</ArticleId><ArticleId IdType="pmc">PMC2937608</ArticleId><ArticleId IdType="pubmed">20592088</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790 10.1371/journal.ppat.1000790</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000790</ArticleId><ArticleId IdType="pmc">PMC2820409</ArticleId><ArticleId IdType="pubmed">20168989</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2&#x2013;9. 10.1086/315215</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315215</ArticleId><ArticleId IdType="pubmed">10608744</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, et al. (2003) High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology
305: 330&#x2013;338. doi: S0042682202917046
</Citation><ArticleIdList><ArticleId IdType="pubmed">12573578</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu IJ, Chiu CY, Chen YC, Wu HC (2011) Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem 286: 9726&#x2013;9736. 10.1074/jbc.M110.170993</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.170993</ArticleId><ArticleId IdType="pmc">PMC3058979</ArticleId><ArticleId IdType="pubmed">21233208</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, et al. (2014) Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 1358&#x2013;1365. 10.1016/S0140-6736(14)61060-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61060-6</ArticleId><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes HR, Crill WD, Chang GJ (2012) Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J 9: 115 10.1186/1743-422X-9-115</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-115</ArticleId><ArticleId IdType="pmc">PMC3424142</ArticleId><ArticleId IdType="pubmed">22709350</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, et al. (2012) Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol 3: 334 10.3389/fimmu.2012.00334</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00334</ArticleId><ArticleId IdType="pmc">PMC3492872</ArticleId><ArticleId IdType="pubmed">23162552</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC (2010) Modeling antibody-enhanced dengue virus infection and disease in mice: protection or pathogenesis? Cell Host Microbe 7: 85&#x2013;86. 10.1016/j.chom.2010.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.02.004</ArticleId><ArticleId IdType="pubmed">20159612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>